Eucrisa (crisaborole) / Pfizer 
Welcome,         Profile    Billing    Logout  
 11 Diseases   8 Trials   8 Trials   513 News 


«12345678»
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Preclinical, Journal:  Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection. (Pubmed Central) -  Apr 4, 2023   
    Taken together, we found that crisaborole reduced itch during psoriasis-like dermatitis and decreased S. aureus skin colonization upon AD-like skin inflammation, which act as additional mechanisms by which crisaborole dampens the immunopathogenesis in mouse models of inflammatory skin diseases. Further examination is warranted to translate these preclinical findings to human disease.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Trial completion date, Trial primary completion date, Adherence:  Eucrisa for Atopic Dermatitis (clinicaltrials.gov) -  Apr 4, 2023   
    P1,  N=40, Active, not recruiting, 
    Further examination is warranted to translate these preclinical findings to human disease. Trial completion date: Apr 2023 --> Jul 2023 | Trial primary completion date: Mar 2023 --> Jun 2023
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Crisaborole inhibits itch and pain by preventing neutrophil infiltration () -  Mar 4, 2023 - Abstract #ISID2023ISID_1334;    
    Additionally, using the cheek skin injection model, we found that S100A8/A9 enhanced not only itch-related behaviors evoked by histamine or chloroquine, but also pain-related behaviors. These findings suggest that the PDE-4 inhibitor reduces itch and pain in atopic dermatitis, in part by inhibiting infiltration of S100A8/9-containing neutrophils.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Journal:  Differences in prescriptions for systemic medications and nonsteroidal topicals among children with atopic dermatitis. (Pubmed Central) -  Feb 2, 2023   
    In a cross-sectional study of patients <18 years old with AD seen at a large children's hospital between 2009 and 2017, we found that nonsteroidal topical and systemic medication prescriptions were associated with older age of the patient, male sex, comorbid atopy, greater healthcare utilization, specialist care, and race/ethnicity. Compared to White patients, Black and Hispanic patients were less likely to be prescribed nonsteroidal topicals and non-White patients were less likely to be prescribed systemic medications, suggesting that further examination of potential disparities in pediatric AD treatment is needed.
  • ||||||||||  Journal:  Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis. (Pubmed Central) -  Jan 28, 2023   
    Data regarding disease prevention are conflicting, however, an abundance of research has transpired regarding amelioration of symptoms and induction of disease clearance by targeting numerous pathological mechanisms. Understanding the pediatric AD phenotype will further advance the field and the development of improved therapeutics.
  • ||||||||||  Daliresp (roflumilast) / AstraZeneca, Takeda, AbbVie, Zoryve (roflumilast cream) / Arcutis
    Journal:  Topical roflumilast (Zoryve) for plaque psoriasis. (Pubmed Central) -  Jan 19, 2023   
    Understanding the pediatric AD phenotype will further advance the field and the development of improved therapeutics. No abstract available
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Trial completion date, Adherence:  Eucrisa for Atopic Dermatitis (clinicaltrials.gov) -  Dec 22, 2022   
    P1,  N=40, Active, not recruiting, 
    No abstract available Trial completion date: Dec 2022 --> Mar 2023
  • ||||||||||  Review, Journal:  Modern Interventions for Pediatric Atopic Dermatitis: An Updated Pharmacologic Approach. (Pubmed Central) -  Dec 20, 2022   
    In this review, we discuss emerging topical and systemic (oral and injectable) treatments in pediatric AD, including topical PDE4 inhibitors and tapinarof, oral JAK inhibitors, and injected biologics including IL-4Rα inhibitor dupilumab, IL-13 inhibitor tralokinumab, IL-13Rα inhibitor lebrikizumab, IL-31Rα inhibitor nemolizumab, and IL-5Rα inhibitor benralizumab...Finally, we propose a therapeutic approach for pediatric AD that incorporates newer therapies including dupilumab and JAK inhibitors, recognizing that these agents may not be universally available or approved. Further trials that include pediatric patients, especially head-to-head studies among therapeutic classes, are needed to clarify the role of emerging treatments.
  • ||||||||||  aspartame/cannabidiol (JW-100) / Jupiter Wellness
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Head-to-Head:  Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis (clinicaltrials.gov) -  Dec 19, 2022   
    P3,  N=0, Withdrawn, 
    Further trials that include pediatric patients, especially head-to-head studies among therapeutic classes, are needed to clarify the role of emerging treatments. N=200 --> 0 | Trial completion date: Apr 2024 --> Dec 2022 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2023 --> Dec 2022
  • ||||||||||  aspartame/cannabidiol (JW-100) / Jupiter Wellness
    Enrollment open, Head-to-Head:  Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis (clinicaltrials.gov) -  Nov 29, 2022   
    P3,  N=200, Recruiting, 
    N=200 --> 0 | Trial completion date: Apr 2024 --> Dec 2022 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2023 --> Dec 2022 Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Treatment options for moderate to severe atopic dermatitis. (Pubmed Central) -  Nov 13, 2022   
    Biologics and Jakinibs should be considered before the traditional systemic anti-inflammatory agents. Clinicians should consider a modified step management for AD as they await the development of national and international guideline recommendations for how best to position the biologics and Jakinibs into the AD treatment algorithm.
  • ||||||||||  aspartame/cannabidiol (JW-100) / Jupiter Wellness
    Trial completion date, Trial primary completion date, Head-to-Head:  Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis (clinicaltrials.gov) -  Nov 2, 2022   
    P3,  N=200, Not yet recruiting, 
    No abstract available Trial completion date: Apr 2022 --> Apr 2024 | Trial primary completion date: Feb 2022 --> Dec 2023
  • ||||||||||  Therapeutic agents for atopic dermatitis in 2022 and beyond (Le Centre Sheraton Montréal) -  Oct 30, 2022 - Abstract #ISAD2022ISAD_105;    
    Some other systemic drugs with various proposed modes of action are in earlier stages of development. Choosing the right form of treatment for atopic dermatitis is a challenge and a complex issue.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Enrollment closed, Enrollment change, Trial primary completion date:  Wearable Skin Sensors to Assess Nocturnal Scratch Behavior (clinicaltrials.gov) -  Sep 28, 2022   
    P=N/A,  N=23, Active, not recruiting, 
    No abstract available Recruiting --> Active, not recruiting | N=15 --> 23 | Trial primary completion date: Mar 2023 --> Oct 2021
  • ||||||||||  Opzelura (ruxolitinib cream) / Incyte, Maruho
    Journal:  What's New in Topicals for Atopic Dermatitis? (Pubmed Central) -  Sep 14, 2022   
    We also review novel targeted therapies that are in early phase clinical trials, including AMTX-100, BEN-2293, and PRN473. Preliminary findings on efficacy and tolerability of most of these agents are promising, but further studies are warranted to evaluate the long-term safety and efficacy of these novel agents against the current standard of care.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Trial primary completion date, Adherence:  Eucrisa for Atopic Dermatitis (clinicaltrials.gov) -  Aug 29, 2022   
    P1,  N=40, Active, not recruiting, 
    Preliminary findings on efficacy and tolerability of most of these agents are promising, but further studies are warranted to evaluate the long-term safety and efficacy of these novel agents against the current standard of care. Trial primary completion date: Aug 2022 --> Dec 2022
  • ||||||||||  Eucrisa (crisaborole) / Pfizer, Eyevinal (ibudilast) / MediciNova, Daliresp (roflumilast) / AstraZeneca, Takeda, AbbVie
    Review, Journal:  An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022. (Pubmed Central) -  Aug 22, 2022   
    Since then, three additional compounds have reached the market a few years later: Crisaborole for atopic dermatitis, Apremilast for psoriatic arthritis and Ibudilast for Krabbe disease. The aim of this review is to provide an overview of the compounds that have reached clinical trials in the last ten years, with a focus on those most recently developed for respiratory, skin and neurological disorders.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Characterization of a murine model of dermatitis induced by oxazolone () -  Aug 16, 2022 - Abstract #ESDR2022ESDR_260;    
    Of note, betamethasone inhibited IL-22 expression whereas tacrolimus increased it and crisaborole had no effect at all. Overall, our results show that this model replicates several AD features and respond to approved topical drugs, making it suitable for screening purposes.
  • ||||||||||  Opzelura (ruxolitinib cream) / Incyte, Maruho
    Review, Journal:  Development of new topical substances for the treatment of atopic dermatitis (Pubmed Central) -  Aug 10, 2022   
    Other phosphodiesterase inhibitors are currently being investigated in clinical trials. Interesting results of clinical studies give hope for further substances and therapeutic approaches.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Biomarker, Trial completion, Trial completion date, Trial primary completion date:  Response of Children With Atopic Dermatitis (Eczema) to Eucrisa (clinicaltrials.gov) -  Jul 19, 2022   
    P4,  N=30, Completed, 
    In studies with low risk of bias, PDE4 inhibitors had a statistically significant risk of producing pain and reduced occurrence of atopic dermatitis exacerbation. Recruiting --> Completed | Trial completion date: Jul 2021 --> Feb 2022 | Trial primary completion date: Jul 2021 --> Feb 2022
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Journal:  Machine Learning for Discovery of New ADORA Modulators. (Pubmed Central) -  Jul 13, 2022   
    At the human AAR, paroxetine did not show any agonist activity at 100 µM, although it displayed binding with a K value of 14.5 µM, suggesting antagonist activity. We have now identified novel modulators of AAR, AAR and AAR subtypes that are clinically used for other therapeutic indications, and which are structurally distinct from previously reported tool compounds or drugs.
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Trial completion date, Trial primary completion date:  Steroid-reducing Effects of Crisaborole (clinicaltrials.gov) -  Jun 30, 2022   
    P4,  N=60, Recruiting, 
    While crisaborole is indicated for mild-to-moderate disease, results suggest that a significant proportion of patients had history of advanced AD therapies suggestive of moderate-to-severe AD. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Trial completion date, Trial primary completion date:  Wearable Skin Sensors to Assess Nocturnal Scratch Behavior (clinicaltrials.gov) -  Jun 9, 2022   
    P=N/A,  N=15, Recruiting, 
    Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Apr 2022 --> Mar 2023 | Trial primary completion date: Apr 2022 --> Mar 2023
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Trial completion date, Trial primary completion date, Adherence:  Eucrisa for Atopic Dermatitis (clinicaltrials.gov) -  May 25, 2022   
    P1,  N=40, Active, not recruiting, 
    No abstract available Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: May 2022 --> Aug 2022